FDA Clears IND for Phase 1B Study of TCB008 in AML

1 year ago 46

An investigational new drug application for TCB008 has been cleared by the FDA. A phase 1B trial will now assess the agent in patients with relapsed/refractory acute myeloid leukemia.

1. Homepage
2. Prostate Cancer
3. FDA Clears IND for Phase 1B Study of TCB008 in AML